Tg Therapeutics (TGTX)

2026-05-07T07:02:48.000Z - 6 days ago

TG Therapeutics reports Q1 EPS 12c, consensus 28c

2026-05-07T03:05:19.000Z - 6 days ago

TG Therapeutics price target raised to $70 from $60 at H.C. Wainwright

May 6, 2026, 8:30 AM EDT - 7 days ago

TG Therapeutics Earnings Call Transcript: Q1 2026

May 6, 2026, 7:00 AM EDT - 7 days ago

TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance

Apr 30, 2026, 7:30 AM EDT - 13 days ago

TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update

2026-04-15T11:48:15.000Z - 4 weeks ago

TG Therapeutics completes enrollment in Briumvi trial

Apr 15, 2026, 7:30 AM EDT - 4 weeks ago

TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI

2026-03-19T12:01:33.000Z - 7 weeks ago

TG Therapeutics secures additional $500M in non-dilutive capital

2026-03-19T12:01:19.000Z - 7 weeks ago

TG Therapeutics board expands share repurchase program to $300M

Mar 19, 2026, 7:30 AM EDT - 7 weeks ago

TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million

2026-03-09T11:40:09.000Z - 2 months ago

TG Therapeutics announces publication of data from studies on Briumvi

Mar 9, 2026, 7:30 AM EDT - 2 months ago

Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis

Mar 6, 2026, 7:30 AM EST - 2 months ago

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting

2026-03-02T12:24:58.000Z - 2 months ago

Precision to get $7.5M in proceeds from TG Therapeutics for azer-cel milestone

DTIL

Mar 2, 2026, 7:01 AM EST - 2 months ago

Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis

DTIL

Feb 26, 2026, 8:30 AM EST - 2 months ago

TG Therapeutics Earnings Call Transcript: Q4 2025

2026-02-26T12:15:51.000Z - 2 months ago

TG Therapeutics sees FY26 revenue $875M-$900M, consensus $897.64M

2026-02-26T12:08:07.000Z - 2 months ago

TG Therapeutics reports Q4 EPS 14c, consensus 33c

2026-02-26T12:06:42.000Z - 2 months ago

TG Therapeutics expects cash to fund business based on current operating plan

Feb 26, 2026, 7:00 AM EST - 2 months ago

TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance

Feb 23, 2026, 7:30 AM EST - 2 months ago

TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update

2026-02-17T12:40:17.000Z - 3 months ago

TG Therapeutics announces long-term data on Briumvi published in JAMA Neurology

Feb 8, 2026, 4:17 PM EST - 3 months ago

TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis

Feb 6, 2026, 7:30 AM EST - 3 months ago

TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

2026-02-02T12:45:26.000Z - 3 months ago

TG Therapeutics price target lowered to $46 from $49 at JPMorgan

Jan 15, 2026, 10:31 AM EST - 4 months ago

These under-the-radar stocks combine fast growth with big upside potential

AGYS ASTH BBT CORT CTRE DCOM DOCN

2026-01-15T00:55:09.000Z - 4 months ago

TG Therapeutics price target raised to $39 from $37 at Goldman Sachs

2026-01-14T15:00:20.000Z - 4 months ago

TG Therapeutics rises 12.2%

2026-01-14T14:40:22.000Z - 4 months ago

Unusually active option classes on open January 14th

BAC BIRK CLOV DVN IBRX ISRG MSTU

2026-01-13T21:30:36.000Z - 4 months ago

TG Therapeutics reports preliminary Q4 revenue $182M, consensus $182.38M

2026-01-13T21:30:27.000Z - 4 months ago

TG Therapeutics sees FY26 revenue $875M-$900M, consensus $895.63M

Jan 13, 2026, 4:30 PM EST - 4 months ago

TG Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 7:30 AM EST - 4 months ago

TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 2, 2025, 12:30 PM EST - 5 months ago

TG Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 28, 2025, 7:30 AM EST - 5 months ago

TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

Nov 12, 2025, 10:00 AM EST - 6 months ago

TG Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Nov 3, 2025, 8:30 AM EST - 6 months ago

TG Therapeutics Earnings Call Transcript: Q3 2025

Oct 31, 2025, 7:30 AM EDT - 6 months ago

TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update

Oct 28, 2025, 7:30 AM EDT - 7 months ago

TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI

Sep 24, 2025, 9:10 AM EDT - 8 months ago

New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment

Sep 10, 2025, 7:30 AM EDT - 8 months ago

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

Sep 8, 2025, 10:30 AM EDT - 8 months ago

TG Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 7:30 AM EDT - 8 months ago

TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment

Sep 4, 2025, 7:30 AM EDT - 8 months ago

TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 10:20 AM EDT - 8 months ago

TG Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 7:30 AM EDT - 9 months ago

TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program

Aug 28, 2025, 8:00 AM EDT - 9 months ago

TG Therapeutics to Participate in the Cantor Global Healthcare Conference

Aug 4, 2025, 8:30 AM EDT - 10 months ago

TG Therapeutics Earnings Call Transcript: Q2 2025

Aug 4, 2025, 7:00 AM EDT - 10 months ago

TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance

Jul 30, 2025, 7:30 AM EDT - 10 months ago

TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update

Jun 10, 2025, 10:40 AM EDT - 1 year ago

TG Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 9, 2025, 4:51 PM EDT - 1 year ago

Evercore ISI's Julian Emanuel says now is the time to buy small-caps

CNS LEU RMBS SFM

Jun 6, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 12:50 PM EDT - 1 year ago

TG Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 27, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting

May 5, 2025, 8:30 AM EDT - 1 year ago

TG Therapeutics Earnings Call Transcript: Q1 2025

May 5, 2025, 7:00 AM EDT - 1 year ago

TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance

Apr 30, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update

Apr 10, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

Apr 7, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals

Mar 7, 2025, 7:30 AM EST - 1 year ago

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

Mar 4, 2025, 7:03 AM EST - 1 year ago

Privia Health, Corcept and three other low-key but high-earnings growth potential stocks to invest in 2025

CORT GILD PRVA TKO

Mar 3, 2025, 8:30 AM EST - 1 year ago

TG Therapeutics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 7:30 AM EST - 1 year ago

TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

Feb 26, 2025, 7:30 AM EST - 1 year ago

TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results and Business Update

Feb 18, 2025, 10:20 AM EST - 1 year ago

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

ARWR AUB CRK CYTK EXE KRYS MARA

Jan 13, 2025, 7:30 PM EST - 1 year ago

TG Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 9, 2025, 7:30 AM EST - 1 year ago

TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Dec 4, 2024, 7:36 AM EST - 1 year ago

20 stocks likely to lag the S&P 500 over the next year — for this one reason

CELH CENX CNXC CRSR CXM FLG GEO

Dec 3, 2024, 10:00 AM EST - 1 year ago

TG Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Nov 29, 2024, 8:00 AM EST - 1 year ago

TG Therapeutics to Participate in the Evercore HealthCONx Conference

Nov 21, 2024, 6:00 AM EST - 1 year ago

TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

Nov 4, 2024, 9:00 AM EST - 1 year ago

FUJIFILM Diosynth Biotechnologies Signs Manufacturing Supply Agreement with TG Therapeutics

Nov 4, 2024, 8:30 AM EST - 1 year ago

TG Therapeutics Earnings Call Transcript: Q3 2024

Nov 1, 2024, 8:06 AM EDT - 1 year ago

TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update

Sep 18, 2024, 7:15 AM EDT - 1 year ago

New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis

Sep 18, 2024, 7:00 AM EDT - 1 year ago

New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment

Sep 5, 2024, 7:30 AM EDT - 1 year ago

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2024 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

Aug 6, 2024, 9:01 AM EDT - 1 year ago

HealthCare Royalty and Blue Owl Announce $250M Debt Financing with TG Therapeutics

Aug 6, 2024, 8:30 AM EDT - 1 year ago

TG Therapeutics Earnings Call Transcript: Q2 2024

Aug 5, 2024, 7:30 AM EDT - 1 year ago

TG Therapeutics to Host Conference Call on Second Quarter 2024 Financial Results and Business Update

Jun 11, 2024, 1:20 PM EDT - 2 years ago

TG Therapeutics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 7, 2024, 7:50 AM EDT - 2 years ago

TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 5, 2024, 1:30 PM EDT - 2 years ago

TG Therapeutics Transcript: Jefferies 2024 Global Healthcare Conference

Jun 3, 2024, 7:30 AM EDT - 2 years ago

TG Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 31, 2024, 7:30 AM EDT - 2 years ago

TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting